Ajinomoto Althea, Inc.

DUBLIN, June 30, 2023 /PRNewswire/ -- The "Global Proteomics Partnering Terms and Agreements 2010 to 2023" report has been added to ResearchAndMarkets.com's offering. The Global Proteomics Partnering Terms and Agreements 2010 to 2023 report provides an understanding and access to the proteomics partnering deals and agreements entered into by the world's leading healthcare companies. Trends in proteomics dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to over 600 proteomics deal records and contract documents where available The leading proteomics deals by value since 2010 Most active proteomics dealmakers since 2010 The leading proteomics partnering resources The Global Proteomics Partnering Terms and Agreements report provides an understanding and access to the proteomics partnering deals and agreements entered into by the world's leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains links to online copies of actual proteomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The initial chapters of this report provide an orientation of proteomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in proteomics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading proteomics deals since 2010. Deals are listed by headline value, signed by big pharma, most active proteomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in proteomics dealmaking with a brief summary followed by a comprehensive listing of proteomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of proteomics partnering deals signed and announced since Jan 2010. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of proteomics partnering deals signed and announced since Jan 2010. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by Proteomics partnering company A-Z, deal type definitions and proteomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in proteomics partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of proteomics technologies and products. Key Topics Covered Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in proteomics dealmaking 2.1. Introduction 2.2. Proteomics partnering over the years 2.3. Most active proteomics dealmakers 2.4. Proteomics partnering by deal type 2.5. Proteomics partnering by therapy area 2.6. Deal terms for proteomics partnering 2.6.1 Proteomics partnering headline values 2.6.2 Proteomics deal upfront payments 2.6.3 Proteomics deal milestone payments 2.6.4 Proteomics royalty rates Chapter 3 - Leading proteomics deals 3.1. Introduction 3.2. Top proteomics deals by value Chapter 4 - Most active proteomics dealmakers 4.1. Introduction 4.2. Most active proteomics dealmakers 4.3. Most active proteomics partnering company profiles Chapter 5 - Proteomics contracts dealmaking directory 5.1. Introduction 5.2. Proteomics contracts dealmaking directory Chapter 6 - Proteomics dealmaking by technology type Appendices Appendix 1 - Proteomics deals by company A-Z Appendix 2 - Proteomics deals by stage of development Appendix 3 - Proteomics deals by deal type Appendix 4 - Proteomics deals by therapy area Deal type definitions Companies Mentioned 3SBio 20/20 BioResponse 21st Century Biochemicals A*STAR Bioinformatics Institute A*STAR Genome Institute of Singapore A*STAR Institute of Microelectronics (IME) AB Analitica Abbvie Abcam Ablynx Abnova Abraxis BioScience Absorption Systems Abt Bio Pharma Solutions Academy for Medical Development & Collaboration Acceleron Pharma Acella Pharmaceuticals ACGT Activiomics ActivX Biosciences ADC Biotechnology Adeona Pharmaceuticals Adimab Aduro BioTech Advaita Advanced Biological Laboratories Advanced BioScience Laboratories Advanced Manufacturing Fund Advinus Therapeutics Aelan Cell Technologies Aestus Therapeutic AEterna Zentaris Affibody Affomix Affymetrix Agilent Technologies AGTC Aileron Therapeutics Ajinomoto AminoScience Alamar Biosciences Albumedix Alexion Pharmaceuticals Allergan Allozyne Almac Diagnostics Almac Group Almirall Alnylam Pharmaceuticals Althea Technologies Altus Pharmaceuticals Alzheimers Research UK Amarantus BioSciences Ambergen Ambrx American College of Cardiology American CryoStem American Health Assistance Foundation Amgen AmorChem Amplimmune Amunix Analytical Testing Laboratory AnaSpec Anchor Therapeutics Angel Biotechnology Anteo Diagnostics Anthera Pharmaceuticals Antigen Discovery Antitope Apeiron Biologics Applied Proteomics Arbor Vita Arbutus Arecor Ariadne Genomics ArmaGen Arrayit Artes Biotechnology Aspera Astellas Pharma AstraZeneca Asuragen ATUM Auburn University Aurigene Discovery Technologies Aushon BioSystems Autism Speaks Autogenesis Auven Therapeutics Avera Heart Hospital of South Dakota Avid Bioservices AvidBiotics Avila Therapeutics Avraham Pharmaceuticals Axil Scientific BaroFold Batavia Biosciences Baxter International Bayer Bayer CropScience Bayer Schering Pharma Baylor College of Medicine BellBrook Labs Bellus Health Berg BGI Americas BG Medicine Bicycle Therapeutics Bill and Melinda Gates Foundation Bio-Techne BioAtla Biocartis Biocius Life Sciences Biocrates Biodesix Bioeasy Diagnostica BioFocus Biogen Biognosys BioGrammatics Biomodels BioNova Cientifica Biopharm BioSante Pharmaceuticals BioSeek Bio Sidus Argentina BioSilta BioSystem Development Biotage Biotechnology and Biological Sciences Research Council (BBSRC) Biotechnology Value Fund Biotest bioVidria BioWa Bioyong BluePen Biomarkers Blue Sky Biotech Boehringer Ingelheim Boehringer Ingelheim Vetmedica BostonGene Bristol-Myers Squibb Bruker Bucher Biotec Bulldog Bio c-LEcta Caladrius Biosciences Caliber Biotherapeutics California Institute for Quantitative Biosciences (QB3) Calixar Cambridge Isotope Laboratories Cambridge Research Biochemicals Camino Partnership Cancer Research Technology Cancer Research UK Cangene Caprion Biosciences Caprion Proteomics Caprotec Bioanalytics For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

May 27, 2021 12:00 UTC -- Investment brings total funding to $9.5 million -- Financing will support preclinical development of its platform and investigational therapy for kidney and other age-related diseases SEATTLE--(BUSINESS WIRE)-- Oisín Biotechnologies, a privately held, preclinical biotechnology company focused on mitigating the effects of age-related diseases, today announced it has completed an oversubscribed round raising $5 million in new seed funding. Led by early-stage investing firm Althea Group, LLC, the round brings Oisín’s total funding to $9.5 million. Oisín will use the proceeds to advance its preclinical pipeline, including its most advanced investigational therapy aimed at chronic kidney disease (CKD). “The support for Oisín’s novel approach to slowing or halting age-related diseases has been strong,” said Matthew Scholz, Oisín Biotechnologies’ chief executive officer and co-founder. “Chronic kidney disease, our initial therapeutic focus, has seen little in the way of therapeutic advances over the past several decades. We believe Oisín is well positioned to address this unmet medical need and will continue to explore other applications in tandem.” Oisín’s highly precise, DNA-based interventions are designed to clear senescent cells, which can trigger aging pathologies and shorten lifespan, from the body. Its proprietary SENSOlytics® technology is a third-wave innovation that uses a novel proteo-lipid vehicle drug delivery platform to induce a senescent cell to trigger apoptosis without harming surrounding healthy cells. In preclinical studies, Oisín’s investigational therapeutics have significantly reduced senescent cell burden in naturally aged mice and extended lifespan by more than 20%, even when the treatment was started in old age. “Oisín’s technology has the potential to upend traditional therapeutic approaches aimed at age-related diseases,” said Raymond Chan, Ph.D., general partner at Althea Group. “The company’s interventions have shown significant early promise and if clinically validated, could have broad applicability. We’re proud to support this talented group and look forward to its continued progress.” Oisín expects the first readouts from its preclinical study in CKD, OB-001, later this year. The initial data will inform its next series of studies and eventually, its first proposed clinical trial design. While using this latest funding to accelerate its CKD work, the company is continuing to progress other planned studies in its preclinical program, advance additional pipeline indications and move towards a regulatory filing to begin its first clinical trial. About Althea Group Althea Group is an early stage venture fund with a track record of significant value creation. Althea’s unique global network spanning finance, academia, public corporations, and start-up operators, enables it to identify, invest in, and grow mission-driven, tenacious founding teams focused on building great products and companies. For more information email us at info@altheagroup.com or visit us at or About Oisín Biotechnologies Oisín is a late preclinical stage company developing therapeutics to reduce the effects of the aging process. Headquartered in Seattle, Washington, the company’s first therapies target senescent cells using its proprietary technology platform, SENSOlytics®. For more information, visit .

New York, March 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Vaccine Contract Manufacturing Industry" - In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations. Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments. Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments. Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience. Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience. Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics. for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics. Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives. Abstract: - Global Vaccine Contract Manufacturing Market to Reach $4.3 Billion by 2027 - Amid the COVID-19 crisis, the global market for Vaccine Contract Manufacturing estimated at US$2.5 Billion in the year 2020, is projected to reach a revised size of US$4.3 Billion by 2027, growing at a CAGR of 8% over the analysis period 2020-2027. Attenuated, one of the segments analyzed in the report, is projected to record a 7.8% CAGR and reach US$1.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Inactivated segment is readjusted to a revised 8.2% CAGR for the next 7-year period. - The U.S. Market is Estimated at $672.6 Million, While China is Forecast to Grow at 12.1% CAGR - The Vaccine Contract Manufacturing market in the U.S. is estimated at US$672.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$960.8 Million by the year 2027 trailing a CAGR of 12% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR. - Subunit-based Segment to Record 8.4% CAGR - In the global Subunit-based segment, USA, Canada, Japan, China and Europe will drive the 7.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$280.9 Million in the year 2020 will reach a projected size of US$475.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$590.6 Million by the year 2027, while Latin America will expand at a 10% CAGR through the analysis period. Select Competitors (Total 34 Featured) - Ajinomoto Althea, Inc. Albany Molecular Research, Inc. Catalent, Inc. Cobra Bio Cytovance Biologics Fujifilm Diosynth Biotechnologies U.S.A., Inc. Icon plc IDT Biologika KBI Biopharma Lonza Read the full report: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Vaccine Contract Manufacturing Competitor Market Share Scenario Worldwide (in %): 2020E Global Competitor Market Shares by Segment 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Vaccine Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Subunit-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Subunit-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Subunit-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Toxoid-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Toxoid-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Toxoid-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for DNA-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for DNA-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for DNA-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Human by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Veterinary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 23: World Historic Review for Veterinary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 24: World 15-Year Perspective for Veterinary by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Market Facts & Figures Market Analytics Table 25: USA Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 26: USA Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 27: USA 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 28: USA Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 29: USA Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 30: USA 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 CANADA Table 31: Canada Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 32: Canada Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 33: Canada 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 34: Canada Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 35: Canada Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 36: Canada 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 JAPAN Table 37: Japan Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 38: Japan Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 39: Japan 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 40: Japan Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 41: Japan Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 42: Japan 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 CHINA Table 43: China Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 44: China Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 45: China 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 46: China Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 47: China Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 48: China 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 EUROPE Market Facts & Figures Market Analytics Table 49: Europe Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 50: Europe Historic Review for Vaccine Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 51: Europe 15-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 52: Europe Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 53: Europe Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 54: Europe 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 55: Europe Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 56: Europe Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 57: Europe 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 FRANCE Table 58: France Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 59: France Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 60: France 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 61: France Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 62: France Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 63: France 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 GERMANY Table 64: Germany Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 65: Germany Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 66: Germany 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 67: Germany Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 68: Germany Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 69: Germany 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 ITALY Table 70: Italy Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 71: Italy Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 72: Italy 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 73: Italy Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 74: Italy Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 75: Italy 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 76: UK Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 77: UK Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 78: UK 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 79: UK Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 80: UK Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 81: UK 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 SPAIN Table 82: Spain Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 83: Spain Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 84: Spain 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 85: Spain Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 86: Spain Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 87: Spain 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 RUSSIA Table 88: Russia Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 89: Russia Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 90: Russia 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 91: Russia Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 92: Russia Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 93: Russia 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 REST OF EUROPE Table 94: Rest of Europe Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 95: Rest of Europe Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 96: Rest of Europe 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 97: Rest of Europe Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 98: Rest of Europe Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 99: Rest of Europe 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 100: Asia-Pacific Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 101: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 102: Asia-Pacific 15-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 Table 103: Asia-Pacific Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 104: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 105: Asia-Pacific 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 106: Asia-Pacific Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 107: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 108: Asia-Pacific 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 AUSTRALIA Table 109: Australia Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 110: Australia Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 111: Australia 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 112: Australia Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 113: Australia Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 114: Australia 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 INDIA Table 115: India Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 116: India Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 117: India 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 118: India Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 119: India Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 120: India 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 SOUTH KOREA Table 121: South Korea Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 122: South Korea Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 123: South Korea 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 124: South Korea Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 125: South Korea Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 126: South Korea 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 REST OF ASIA-PACIFIC Table 127: Rest of Asia-Pacific Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 128: Rest of Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 129: Rest of Asia-Pacific 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 130: Rest of Asia-Pacific Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 131: Rest of Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 132: Rest of Asia-Pacific 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 LATIN AMERICA Table 133: Latin America Current & Future Analysis for Vaccine Please contact our Customer Support Center to get the complete Table of Contents Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001